Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3047% below fair value
$2.88−0.15 (-4.95%)
Close on Nov 17, 2026Market cap $232.05MP/E 12.5Yield –
Protalix BioTherapeutics market cap
Market capitalization is the share price multiplied by the number of shares outstanding.
Protalix BioTherapeutics's market cap was $255.04M on Nov 11, 2026, against $152.65M a year earlier. Over the last 5 years it ranged from $34.15M to $255.04M, with a median of $112.96M.
Market Cap at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $255.04M | +65.2% |
| 2025 | Dec 31, 2025 | $154.36M | +4.5% |
| 2024 | Dec 31, 2024 | $147.64M | +20.4% |
| 2023 | Dec 29, 2023 | $122.64M | +90.5% |
| 2022 | Dec 30, 2022 | $64.37M | +88.5% |
| 2021 | Dec 31, 2021 | $34.15M | -39.2% |
| 2020 | Dec 31, 2020 | $56.17M | +15.4% |
| 2019 | Dec 31, 2019 | $48.66M | -99.6% |
| 2018 | Dec 31, 2018 | $11.29B | +12192.4% |
| 2017 | Dec 29, 2017 | $91.88M | +105.1% |
| 2016 | Dec 30, 2016 | $44.80M | -53.0% |
| 2015 | Dec 31, 2015 | $95.33M | -44.1% |
| 2014 | Dec 31, 2014 | $170.67M | -52.4% |
| 2013 | Dec 31, 2013 | $358.68M | -23.2% |
| 2012 | Dec 31, 2012 | $467.31M | -10.7% |
| 2011 | Jul 29, 2011 | $523.24M | – |
See a number that looks wrong?